SangHak Yi

SangHak Yi

Auto-generated profile, based on publicly available information

SangHak Yi

Department of Neurology, Wonkwang University School of Medicine and Regional Cardiocerebrovascular Center, Iksan, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
MWMin Jeong Wang
Min Jeong Wang
SYSangHak Yi
SangHak Yi
JHJee-Young Han
Jee-Young Han
SPSo Young Park
So Young Park
JJJae-Won Jang
Jae-Won Jang
SKSangYun Kim
SangYun Kim
Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer’s disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minimally invasive tools for AD diagnostics. In the present study, the recently developed Multimer Detection System (MDS) for AD, a new enzyme-linked immunosorbent assay for measuring Aβ oligomers selectively, was used to detect Aβ oligomers in the plasma of patients with AD and healthy control individuals. Twenty-four patients with AD and 37 cognitively normal control individuals underwent extensive clinical evaluations as follows: blood sampling; detailed neuropsychological tests; brain magnetic resonance imaging; cerebrospinal fluid (CSF) measurement of Aβ42, phosphorylated tau protein (pTau), and total tau protein (tTau); and 11C-Pittsburgh compound B (PIB) positron emission tomography. Pearson’s correlation analyses between the estimations of Aβ oligomer levels by MDS and other conventional AD biomarkers (CSF Aβ42, pTau, and tTau, as well as PIB standardized uptake value ratio [PIB SUVR]) were conducted. ROC analyses were used to compare the diagnostic performance of each biomarker. The plasma levels of Aβ oligomers by MDS were higher in patients with AD than in normal control individuals, and they correlated well with conventional AD biomarkers (levels of Aβ oligomers by MDS vs. CSF Aβ42, r = −0.443; PIB SUVR, r = 0.430; CSF pTau, r = 0.530; CSF tTau, r = 0.604). The sensitivity and specificity of detecting plasma Aβ oligomers by MDS for differentiating AD from the normal controls were 78.3% and 86.5%, respectively. The AUC for plasma Aβ oligomers by MDS was 0.844, which was not significantly different from the AUC of other biomarkers (p = 0.250). Plasma levels of Aβ oligomers could be assessed using MDS, which might be a simple, noninvasive, and accessible assay for evaluating brain amyloid deposition related to AD pathology.

13 November 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DHDong Hwan Ho
Dong Hwan Ho
SYSanghak Yi
Sanghak Yi
HSHyemyung Seo
Hyemyung Seo
ISIlhong Son
Ilhong Son
WSWongi Seol
Wongi Seol
Parkinson’s disease (PD) is a difficult disease to diagnose although it is the second most common neurodegenerative disease. Recent studies show that exosome isolated from urine contains LRRK2 or DJ-1, proteins whose mutations cause PD. To investigate a potential use for urine exosomes as a tool for PD diagnosis, we compared levels of LRRK2,α-synuclein, and DJ-1 in urine exosomes isolated from Korean PD patients and non-PD controls. LRRK2 and DJ-1, but notα-synuclein, were detected in the urine exosome samples, as reported previously. We initially could not detect any significant difference in these protein levels between the patient and the control groups. However, when age, disease duration, L-dopa daily dose, and gender were considered as analytical parameters, LRRK2 and DJ-1 protein levels showed clear gender-dependent differences. In addition, DJ-1 level was significantly higher (1.7-fold) in male patients with PD than that in male non-PD controls and increased in an age-dependent manner in male patients with PD. Our observation might provide a clue to lead to a novel biomarker for PD diagnosis, at least in males.

6 May 2016 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
MWMin Jeong Wang
Min Jeong Wang
SYSangHak Yi
SangHak Yi
JHJee-Young Han
Jee-Young Han
SPSo Young Park
So Young Park
JJJae-Won Jang
Jae-Won Jang
SKSangYun Kim
SangYun Kim
Background: Recently, a Korean research group suggested a consensus protocol, based on the Alzheimer’s Disease Neuroimaging Initiative study protocol but with modifications for minimizing the confounding factors, for the evaluation of cerebrospinal fluid (CSF) biomarkers. Objective: Here, we analyzed fluid and imaging biomarkers of Alzheimer’s disease (AD) in Korean population. We used the updated protocol to propose a more accurate CSF biomarker value for the diagnosis of AD. Methods: Twenty-seven patients with AD and 30 cognitively normal controls (NC) were enrolled. CSF was collected from 55 subjects (patients with AD = 26, NC = 29) following the Korea consensus protocol. CSF biomarkers were measured using the INNO-BIA AlzBio3 immunoassay, and Pittsburgh compound B (PIB) positron emission tomography (PET) scans were also performed. Results: The cutoff values of CSF amyloid beta 1-42 (Aβ 42 ), total tau (t-Tau), and phosphorylated tau (p-Tau) proteins were 357.1 pg/ml, 83.35 pg/ml, and 38.00 pg/ml, respectively. The cutoff values of CSF t-Tau/Aβ 42 and p-Tau/Aβ 42 ratio- were 0.210 (sensitivity 100%, specificity 86.21%) and 0.1350 (sensitivity 88.46%, specificity of 92.86%). The concordance rate with PIB-PET was higher using the CSF t-Tau/Aβ 42 ratio ( κ = 0.849, CI 0.71–0.99) than CSF Aβ 42 alone ( κ = 0.703, CI 0.51–0.89). Conclusions: Here, we improved controversial factors associated with the previous CSF study protocol and suggested a new cutoff value for the diagnosis of AD. Our results showed good diagnostic performance for differentiation of AD. Thus, we expect our findings could be a cornerstone in the establishment and clinical application of biomarkers for AD diagnosis.

1 January 2018 in Dementia and Neurocognitive Disorders
Verified
Journal Article
Open access
PDF file
MKMin Ju Kang
Min Ju Kang
YPYoung Ho Park
Young Ho Park
SKSangYun Kim
SangYun Kim
SYSangHak Yi
SangHak Yi
Kang MJ, et al. Dement Neurocognitive Disord. 2018 Mar;17(1):32-36. https://doi.org/10.12779/dnd.2018.17.1.32

1 February 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
SYSangHak Yi
SangHak Yi
HPHyun-Young Park
Hyun-Young Park

1 January 2018 in Dementia and Neurocognitive Disorders
Verified
Journal Article
Open access
MOMi Jin Oh
Mi Jin Oh
SKSangYun Kim
SangYun Kim
YPYoung Ho Park
Young Ho Park
JSJeewon Suh
Jeewon Suh
SYSangHak Yi
SangHak Yi